Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

DeepDyve requires Javascript to function. Please enable Javascript on your browser to continue.

Kidney Cancer

Subject Areas: Nephrology
Publisher: IOS Press - IOS Press
ISSN: 2468-4562
SJR: 8

Download Only

Journal Article

Adjuvant Therapy in Renal Cell Carcinoma: Are We Ready for Prime Time?

Wang, Luke L.; Saidian, Ava; Pan, Elizabeth; Panian, Justine; Derweesh, Ithaar H.; McKay, Rana R.

2023 Kidney Cancer

doi:10.3233/kca-220014

The standard of care for localized renal cell carcinoma (RCC) is radical or partial nephrectomy. Despite complete resection, a subset of patients will develop locoregional recurrence or metastatic disease. Adjuvant immunotherapy has been studied since the 1980 s as the primary method to mitigate...
Download Only

Journal Article

Erratum to: SETD2 Regulates the Methylation of Translation Elongation Factor eEF1A1 in Clear Cell Renal Cell Carcinoma

Hapke, Robert; Venton, Lindsay; Rose, Kristie Lindsay; Sheng, Quanhu; Reddy, Anupama; Prather, Rebecca; Jones, Angela; Rathmell, W. Kimryn; Haak, Scott M.

2023 Kidney Cancer

doi:10.3233/kca-229010
Download Only

Journal Article

Erratum to: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma

Sharma, Akanksha; Elias, Roy; Christie, Alana; Williams, Noelle S.; Pedrosa, Ivan; Bjarnason, Georg A.; Brugarolas, James

2023 Kidney Cancer

doi:10.3233/kca-229030
Download Only

Journal Article

Clinical Trials Corner: Raising the SABR to Renal Cell Carcinoma

Parikh, Mamta

2023 Kidney Cancer

doi:10.3233/kca-239001
Download Only

Journal Article

Efficacy of Therapy vs Surveillance in Patients with Resected Early-Stage Intermediate to High-Risk Renal Cell Carcinoma

Major, C. Kendall; Rodriguez, Carlos I.; Haas, Naomi B.

2023 Kidney Cancer

doi:10.3233/kca-220018

BACKGROUND:The historical standard of care for locally advanced renal cell carcinoma (RCC) is nephrectomy + active surveillance. Despite a high recurrence rate ( 40%), adjuvant therapy was previously not included in the standard of care. This review of adjuvant pharmacotherapy reflects...
Download Only

Journal Article

Axitinib beyond first-line therapy of Metastatic Renal Cell Carcinoma: Real World Data from the STAR-TOR registry

Uhlig, Annemarie; Uhlig, Johannes; Woike, Michael; Fischer, Thomas; Trojan, Lutz; Bergmann, Lothar; Bögemann, Martin; Goebell, Peter J.; Rink, Michael; Schlack, Katrin; Leitsmann, Marianne; Strauß, Arne

2023 Kidney Cancer

doi:10.3233/kca-220011

Objective:To evaluate the effectiveness and safety profile of the tyrosine kinase inhibitor Axitinib for patients with advanced or metastatic renal cell carcinoma (a/mRCC) in a real-world setting.Methods:Adult patients from the German non-interventional post-approval multicenter STAR-TOR registry...
Download Only

Journal Article

Influences of Age and Comorbidities on Indication for Partial Nephrectomy: A Systematic Review

Cignoli, Daniele; Fallara, Giuseppe; Re, Chiara; Cei, Francesco; Musso, Giacomo; Basile, Giuseppe; Rosiello, Giuseppe; Salonia, Andrea; Larcher, Alessandro; Montorsi, Francesco; Capitanio, Umberto

2023 Kidney Cancer

doi:10.3233/kca-230001

BACKGROUND:The influence of age and comorbidities during decision-making for patients with renal cell carcinoma remains controversial.OBJECTIVE:To comprehensively review the available evidence regarding the impacts of age and comorbidities on the decision to perform partial nephrectomy...
Download Only

Journal Article

MET Inhibitors for Papillary Renal Cell Carcinoma

Brundage, James Nicholas; Sahu, Kamal Kant; Maughan, Benjamin Louis

2023 Kidney Cancer

doi:10.3233/kca-230005

BACKGROUND:Papillary renal cell carcinoma (PRCC) has a relatively poor prognosis in the metastatic setting. In contrast to clear cell kidney cancer, there are limited treatment options specifically tested in PRCC. Alterations in the MET pathway are common in PRCC and may play a pivotal role in...
Download Only

Journal Article

Antigenic targets in clear cell renal cell carcinoma

Schindler, Nicholas R.; Braun, David A.

2023 Kidney Cancer

doi:10.3233/kca-230006 pmid:38014393

Immune checkpoint inhibitors (ICIs) have transformed the management of advanced renal cell carcinoma (RCC), but most patients still do not receive a long-term benefit from these therapies, and many experience off-target, immune-related adverse effects. RCC is also different from many other...
Download Only

Journal Article

Clinical Trials Corner: The Challenge to Establish Optimal Treatment After Progression on Checkpoint Inhibitors

Parikh, Mamta

2023 Kidney Cancer

doi:10.3233/kca-239002

results per page

Prev
1
2
Next